HSV Meningitis Suppression Treatment
For recurrent HSV-2 meningitis (Mollaret's meningitis), suppressive antiviral therapy with valacyclovir 500 mg twice daily is NOT recommended, as it has been proven ineffective in preventing recurrences and may paradoxically increase rebound episodes after discontinuation. 1, 2
Treatment Approach for Recurrent HSV-2 Meningitis
Acute Episode Management
For acute episodes of recurrent HSV-2 meningitis, the treatment differs from first episodes:
- Established recurrent cases: Oral therapy may be used for the entire course 1
- Regimen: Valacyclovir 1 g three times daily for 14 days 1
- Alternative for first episode: Acyclovir 10 mg/kg IV every 8 hours until fever/headache resolve, then valacyclovir 1 g TID to complete 14 days 1
Why Standard Suppressive Therapy Fails
The landmark randomized controlled trial demonstrated that valacyclovir 500 mg twice daily:
- Did NOT prevent recurrent meningitis episodes during the treatment year 2
- Caused a significant rebound effect with 3.29-fold increased risk of recurrence in the year after stopping (95% CI: 10.06-10.21) 2
- The dose was likely insufficient for CNS penetration, though it did protect against mucocutaneous lesions 2
This is fundamentally different from genital herpes suppression, where the same dose is effective because CNS penetration is not required.
Patient-Initiated Episodic Therapy Strategy
The most practical approach for recurrent HSV-2 meningitis is patient-initiated episodic treatment at symptom onset 3, 4:
- Provide patients with a prescription for valacyclovir 1 g TID
- Instruct them to start immediately when prodromal symptoms appear (headache, photophobia, fever)
- This may attenuate clinical severity and reduce morbidity 3
- Complete a 7-14 day course depending on symptom resolution
Clinical Context and Pitfalls
Critical distinction: HSV meningitis is self-limiting in immunocompetent patients, unlike HSV encephalitis which has high morbidity/mortality 1, 5. One-third of patients experience 1-4 episodes over time, but neurologic sequelae are rare in immunocompetent hosts 2, 5.
Common pitfalls to avoid:
- Do not use the genital herpes suppression dose (500 mg BID) for CNS disease—it doesn't work 1, 2
- Do not confuse HSV meningitis with HSV encephalitis (which requires 14-21 days IV acyclovir) 1, 6
- Avoid prolonged IV therapy in immunocompetent patients with meningitis—oral therapy is sufficient for recurrent cases 1, 5
Special Populations
Immunocompromised patients: These patients DO benefit from antiviral therapy and have improved neurologic outcomes with treatment 5. Consider:
- Longer treatment duration
- Possible role for higher-dose suppression (though not formally studied)
- More aggressive acute management
Current Practice Patterns
A 2022 survey of infectious disease specialists revealed highly variable practices, with 61% using IV acyclovir followed by oral valacyclovir, and median total duration of 7 days 7. However, this variability reflects the lack of high-quality evidence rather than optimal practice.
Bottom line: Focus on patient education about the benign, recurrent nature of this condition 4, 8, provide patient-initiated episodic therapy, and avoid the false reassurance of ineffective suppressive regimens that may worsen outcomes.